We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close
Focus On
NEW In-House Counsel | Insurance | Intellectual Property | Immigration | Natural Resources | Real Estate | Tax

Some answers, more questions on free trade

Thursday, January 22, 2015 @ 7:00 PM | By Ryan Evans and Geoffrey Mowatt

Critics of the newly minted “free-trade” agreement between Canada and the European Union (the Comprehensive Economic and Trade Agreement), were quick to decry that it would be a game-changer for the pharmaceutical industry and would drive up the cost of prescription drugs in Canada. The concern was based in large part on news that the Canadian government had agreed to provide additional patent protection for qualifying pharmaceutical products. The lack of detail concerning this obligation spurred a raging debate as to whether the deal amounted to...